Ublituximab (Briumvi)

Ublituximab is a disease modifying therapy (DMT) for ‘active’ relapsing MS. Its brand name is Briumvi and you take it as an infusion. It’s a monoclonal antibody, one of the more effective types of MS drugs. 

Jump to:

Who can take ublituximab (Briumvi)?

How does ublituximab (Briumvi) work?

How well does ublituximab (Briumvi) work?

What are the side effects of ublituximab (Briumvi)?

Ublituximab (Briumvi) and pregnancy, breastfeeding and contraception

Who can take ublituximab (Briumvi)?

You can have ublituximab (Briumvi) across the UK if:

  • you have ‘active’ relapsing MS. That means you’ve had a recent relapse and/or MRI scans show that you have new lesions.

You might be offered ublituximab (Briumvi) as your first DMT, or if the one you’re already taking isn’t controlling your MS well enough.

Back to the top

How does ublituximab (Briumvi) work?

Special types of cells in your immune system called B cells are thought to cause a lot of the damage in MS. They normally kill viruses and bacteria that get into your body, but in MS they damage nerves. They do this by stripping off the covering of myelin from nerves in your brain and spinal cord. Myelin protects nerves from damage, and helps messages travel along them.

Ublituximab (Briumvi) is a monoclonal antibody drug. These artificial antibodies, made in a laboratory, stick to the surface of the B cells and kill them. This leads to fewer B cells that can damage the myelin covering around your nerves. This means you get relapses much less often.

You also get far fewer lesions. Lesions are areas of damage to the nerves in your brain or spinal cord. A doctor can see lesions on your MRI scans.

This drug also slows down how fast people’s disability gets worse.

After your first infusion (on a lower starting dose), you only need an hour-long infusion of ublituximab (Briumvi) twice a year. An infusion is when doctors give you a drug through a drip in your arm. This happens in a hospital.

Back to the top

How well does ublituximab (Briumvi) work?

Two trials compared ublituximab (Briumvi) to a drug already used to treat MS called teriflumonide (teriflunomide’s brand name is Aubagio). Ublituximab (Briumvi) was much better than teriflunomide at reducing how many relapses people got. It was also better at reducing how many lesions doctors could see on MRI scans.

Relapses dropped by: 49-59% compared to teriflunomide

This means that in the trials, over two years, on average people saw a drop of 49-59% in the number of relapses they had. This was compared to people who took teriflunomide.

When it came to how well ublituximab (Briumvi) slowed down disability getting worse, in these trials it had about the same effect as teriflunomide. Terifunomide reduces disability getting worse by around 30%.

Back to the top

What are the side effects of ublituximab (Briumvi)?

Within 24 hours of the first infusion of the drug, around half of people get an infusion reaction. After the second infusion this drops to under one in ten people, falling even lower for infusions after that.

These reactions can involve fever, chills, headache, a faster heartbeat, feeling sick, stomach pain, sore throat, or a rash or red or itchy skin. To lower the risk of a reaction, before each infusion you’re given a steroid and an anti-histamine (an anti-allergy medicine). You’ll be monitored during and after the first infusion in case you get a more serious reaction.

Ublituximab (Briumvi) lowers your levels of white blood cells. These cells fight infections. As a result, over half of people in trials got some kind of infection, mostly mild to moderate ones. Very common were things like colds, and nose and throat infections (around one in three people got these). Less than one in 10 got pain in the arms or legs, or infections caused by herpes viruses. Around one in 20 people got chest infections like bronchitis or pneumonia.

Back to the top

Ublituximab (Briumvi) and pregnancy, breastfeeding and contraception

Pregnancy

Ublituximab (Briumvi) doesn’t have a licence to be used in pregnancy. We don’t have enough information on how this drug might affect the unborn child. Its makers say, unless you’ve spoken to your doctor first, you shouldn’t take this drug if you’re pregnant, or if you want to have a baby.

If you do decide to stop this drug to have a baby, you should go back on it straight after the birth to cut your risk of a relapse.

If you and your partner want to have a child, discuss this with your neurologist. If you think you’ve become pregnant, let your medical team know at once. Never stop your DMT without first getting their advice.

Breastfeeding

We don’t know if ublituximab (Briumvi) can get into breast milk. Talk to your doctor about the best way to feed your baby if you take Briumvi.

Contraception

If you can get pregnant, the makers of ublituximab (Briumvi) recommend that you use contraception. This should be during your treatment and for four months after your last infusion. Ask your medical team for advice about contraception. 

Back to the top